Is AI Capable of Real-World Drug Discovery?

Small-molecule drug discovery frequently operates in regimes where slight structural changes have large consequences, and current AI methods trained on mass data may perform poorly in such situations. It explicitly delimits the regime of "slight structural change, large biological consequence" as a difficult zone for AI methods, rather than discussing AI capability in drug discovery in general terms. This is an argumentative judgment the article builds from two case studies, resting on the premises of large consequences from structural change and training on mass data; no quantitative benchmark is given.

For a substantial fraction of drug-discovery projects, limited biological understanding and sparse data further constrain progress and define regimes where AI approaches remain difficult to apply. It places sparse data alongside limited biological understanding as constraining conditions, indicating that the difficulty arises not only from algorithms but also from the knowledge and data conditions of the projects themselves. A discursive statement in the article; no project proportions, sample sizes, or statistics are provided.

In two case studies characterized by structural and biochemical data, the close integration of computational and medicinal chemistry coupled with a deep understanding of chemical shape and protein interactions enabled targeted computational molecular design to produce disproportionate gains in efficacy and selectivity. It uses concrete cases to show what the combination of computation, medicinal chemistry, and understanding of shape and interactions can achieve, rather than relying on data-driven pattern recognition alone. Based on two case studies characterized by structural and biochemical data; the article does not give specific compounds, targets, numerical values, or effect sizes.

These examples highlight a challenge for current AI methods: sensitivity to subtle, low-data perturbations; for AI to achieve a transformative impact, it must move beyond pattern recognition to understand, or explicitly simulate, the mechanistic "why" linking subtle structural changes to biological outcomes. It sets mechanistic understanding or explicit simulation as the precondition for AI to achieve transformative impact in drug discovery, and on that basis delineates opportunities for AI to complement human efforts rather than act as a stand-alone solution. This is the authors' viewpoint and directional claim derived from the case studies, an argument and outlook rather than an experimentally verified conclusion.

The article's conclusions address small-molecule drug discovery, especially projects where structural changes have large consequences, biological understanding is limited, and data are sparse; its argument rests on two case studies characterized by structural and biochemical data, so the described path of closely integrating computational and medicinal chemistry and attending to chemical shape and protein interactions applies to design settings where such structural information is available and human experts are deeply involved. The article also indicates that, until AI possesses mechanistic understanding or explicit simulation capability, its realistic role is to complement human efforts rather than serve as a stand-alone solution.

A careful reader would still watch for the specific targets, compounds, and structure-activity details of the two case studies, which are not elaborated here, so the magnitude and reproducibility of the "disproportionate gains" await the full text; moreover, how AI moves from pattern recognition to mechanistic understanding or explicit simulation is offered as a direction rather than a realized path, leaving its feasibility and required data conditions open questions.